BR9814080A - Uso de compostos para atividade anti-prurìtica - Google Patents

Uso de compostos para atividade anti-prurìtica

Info

Publication number
BR9814080A
BR9814080A BR9814080-9A BR9814080A BR9814080A BR 9814080 A BR9814080 A BR 9814080A BR 9814080 A BR9814080 A BR 9814080A BR 9814080 A BR9814080 A BR 9814080A
Authority
BR
Brazil
Prior art keywords
compounds
pruritic activity
activity
pruritic
pruritically
Prior art date
Application number
BR9814080-9A
Other languages
English (en)
Inventor
Don E Griswold
Siegfried Benjamin Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR9814080A publication Critical patent/BR9814080A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE COMPOSTOS PARA ATIVIDADE ANTI-PRURìTICA" A presente invenção refere-se a derivados de xantinas 8-substituídas que são usados na profilaxia ou terapida de doenças ou distúrbios que têm um componente prurítico.
BR9814080-9A 1997-10-17 1998-10-16 Uso de compostos para atividade anti-prurìtica BR9814080A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17
PCT/US1998/021886 WO1999020280A1 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Publications (1)

Publication Number Publication Date
BR9814080A true BR9814080A (pt) 2000-09-26

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814080-9A BR9814080A (pt) 1997-10-17 1998-10-16 Uso de compostos para atividade anti-prurìtica

Country Status (18)

Country Link
EP (1) EP1030666A4 (pt)
JP (1) JP2001520196A (pt)
KR (1) KR20010031149A (pt)
CN (1) CN1306426A (pt)
AR (1) AR015966A1 (pt)
AU (1) AU740875B2 (pt)
BR (1) BR9814080A (pt)
CA (1) CA2306985A1 (pt)
CO (1) CO4810374A1 (pt)
CZ (1) CZ20001376A3 (pt)
HU (1) HUP0003792A3 (pt)
IL (1) IL135581A0 (pt)
NO (1) NO20001847L (pt)
NZ (1) NZ503551A (pt)
PL (1) PL341062A1 (pt)
TR (1) TR200001040T2 (pt)
WO (1) WO1999020280A1 (pt)
ZA (1) ZA989450B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364910A1 (en) 2001-01-31 2004-12-27 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
EE200300362A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid
IL156413A0 (en) 2001-01-31 2004-01-04 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
EP1647274A4 (en) * 2003-07-17 2008-12-10 Ono Pharmaceutical Co REMEDY AGAINST PRURIT COMPRISING A PIPERIDINE DERIVATIVE AS AN ACTIVE INGREDIENT
JP2005187458A (ja) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd シロミラストまたはその塩を有効成分とする掻痒治療剤
WO2005053672A1 (ja) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. シロミラストまたはその塩を有効成分とする掻痒治療剤
NZ548496A (en) * 2004-02-14 2010-02-26 Smithkline Beecham Corp Medicaments with HM74A receptor activity for disorder of lipid metabolism
JP2008137892A (ja) * 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
ATE487719T1 (de) 2005-08-10 2010-11-15 Glaxosmithkline Llc Xanthinderivate als selektive hm74a-agonisten
WO2007097317A1 (ja) * 2006-02-21 2007-08-30 Eisai R & D Management Co., Ltd. ４－（３－ベンゾイルアミノフェニル）－６，７－ジメトキシ－２－メチルアミノキナゾリン誘導体
TWI404709B (zh) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
WO2008099887A1 (ja) 2007-02-16 2008-08-21 Eisai R & D Management Co., Ltd. メチル ｎ－［３－（６，７－ジメトキシ－２－メチルアミノキナゾリン－４－イル）フェニル］テレフタラミックアシッドの結晶、非晶質体または塩
EP2189450B1 (en) 2007-08-17 2011-12-21 Eisai R&D Management Co., Ltd. Method for producing quinazoline derivative
JP5060561B2 (ja) 2007-08-17 2012-10-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規外用剤
EP2727594B1 (en) 2011-06-28 2017-12-20 Mitsubishi Tanabe Pharma Corporation Naphtalene compounds to treat itch
PT3251675T (pt) 2015-01-30 2021-05-25 Shanton Pharma Pte Ltd Prevenção ou tratamento de doença de ácido úrico ou gota

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194345T1 (de) * 1990-12-21 2000-07-15 Beecham Group Plc Xanthinderivate
EP0889886B1 (de) * 1996-03-26 2002-09-18 ALTANA Pharma AG Neue in 6-position substituierte phenanthridine
ATE228131T1 (de) * 1996-05-15 2002-12-15 Altana Pharma Ag Imidazopyridine
AU6825898A (en) * 1997-03-07 1998-09-29 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel tetrazoles
BR9810409A (pt) * 1997-03-18 2000-08-22 Basf Ag Métodos e composições para a modulação de responsividade a corticosteróides
AU8106598A (en) * 1997-06-03 1998-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine

Also Published As

Publication number Publication date
CA2306985A1 (en) 1999-04-29
NO20001847D0 (no) 2000-04-10
PL341062A1 (en) 2001-03-26
CZ20001376A3 (cs) 2002-06-12
AU1093899A (en) 1999-05-10
EP1030666A1 (en) 2000-08-30
TR200001040T2 (tr) 2001-01-22
NZ503551A (en) 2002-05-31
WO1999020280A1 (en) 1999-04-29
IL135581A0 (en) 2001-05-20
KR20010031149A (ko) 2001-04-16
HUP0003792A3 (en) 2001-12-28
AU740875B2 (en) 2001-11-15
ZA989450B (en) 1999-04-19
AR015966A1 (es) 2001-05-30
CO4810374A1 (es) 1999-06-30
JP2001520196A (ja) 2001-10-30
HUP0003792A2 (hu) 2001-10-28
EP1030666A4 (en) 2002-10-16
NO20001847L (no) 2000-04-10
CN1306426A (zh) 2001-08-01

Similar Documents

Publication Publication Date Title
BR9814080A (pt) Uso de compostos para atividade anti-prurìtica
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0113146A (pt) Derivados de prolina e uso destes como drogas
EP0105635A3 (en) Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therepeutic agents
FI945363A (fi) Uusia merkaptoasetyyliamidopyridatso (1,2)pyridatsiini-, pyratsolo(1,2)pyridatsiini-, pyridatso (1,2-a)(1,2)diatsepiini- ja pyratsolo(1,2-a)(1,2)diatsepiinijohdannaisia, jotka ovat käyttökelpoisia enkefalisaasin ja ACE:n estäjinä
BR9812944A (pt) Inibidores bicìclicos da cinase
SV1999000147A (es) Derivados de 4, 4-biarilpiperidina ref. pc10083/82759/bb
BR9907886A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.
DE69333109D1 (de) Therapeutische nukleoside
NO965516D0 (no) Sterolderivater anvendt til regulering av meiose
BG101110A (en) Substituted pyrimidine compounds and their application
BR0211863A (pt) 1-alquil ou 1-cicloalquiltriazolo[4,3a]quinazolin-5-onas como inibidores da fosfodiesterase
FI946043A (fi) Sokeripäällysteinen farmaseuttinen annosyksikkö
BR0113590A (pt) 7-oxo-piridopirimidinas
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
AU623805B2 (en) New use of anti-progestomimetic compounds
MX9401080A (es) Compuestos heteroaromaticos.
DK102892D0 (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
MX9303392A (es) Derivados de imidazo benzoxazin-1-ona substituidos y proceso para su preparacion.
BR9811631A (pt) Derivado de ácido carboxìlico e uso do mesmo
ES8705438A1 (es) Procedimiento para preparar derivados de pirazol-(1,5-a)piridina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.